Key Developments For Luminex Corp
Luminex Corp (LMNX.O) (Consolidated Issue listed on NASDAQ Global Market)
Luminex Corporation Lowers High End Of Prior FY 2009 Revenue Guidance To A Range In Line With Analysts' Estimates
Luminex Corporation adjusted fiscal 2009 revenue guidance to $118-$126 million from between $118-$132 million. According to Reuters Estimates, analysts were expecting the Company to report revenues of $119 million for the same period.
Luminex Corporation Receives 510(K) Clearance For New Cystic Fibrosis Test
Luminex Corporation announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new cystic fibrosis (CF) test: the xTAG Cystic Fibrosis 39 Kit v2. Designed with years of feedback from clinicians and technicians, the newly cleared xTAG test detects for 39 CF-causing gene mutations. It is used to screen potential parents to determine if they are carriers of CF-causing gene mutations, and as an aid in newborn screening and in confirmatory diagnostic testing in newborns and children. Cystic fibrosis is a chronic inherited genetic disease in which the body produces thick and sticky mucus that can clog the lungs and affect the digestive system. It is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. More than 1,500 such mutations have been identified to datei.
Luminex Corporation Lowers FY 2009 Revenue Outlook
Luminex Corporation announced that for fiscal 2009, it has lowered revenue outlook from between $125 million and $135 million to between $118 million and $132 million. The adjusted full year figures represent an increase of between 13% and 26% over reported 2008 revenue. According to Reuters Estimates, analysts were expecting the Company to report revenue of $125 million for fiscal 2009.
Luminex Corporation Announces FDA Clearance For Update To xTAG Respiratory Viral Panel Package Insert
Luminex Corporation announced that U.S. Food and Drug Administration (FDA) has cleared labeling updates for the Company's xTAG Respiratory Viral Panel (RVP) to include data about the performance of the test in humans infected with the pandemic strain of influenza A, 2009 influenza A/H1N1, which is sometimes referred to as 'swine flu'. The test's labeling has been updated to include information from two new studies that demonstrate that xTAG RVP can be an effective aid in the detection of 2009 Influenza A/HIN1, but cannot identify the hemagglutinin gene of the 2009 Influenza A/H1N1 in clinical specimens.
Luminex Corporation Announces Full Commercial Launch Of High Throughput FLEXMAP 3D Multiplexing System
Luminex Corporation announced the full market release of its FLEXMAP 3DTM system, a high-throughput multiplexing instrument that allows scientists to simultaneously perform up to 500 tests on a single sample. Created with input from scientists worldwide, FLEXMAP 3D was designed to meet the needs of medium and high-volume laboratories, such as academic, reference and pharmaceutical research laboratories. The FLEXMAP 3D multiplexing system`s ability to conduct many tests at once can significantly enhance the efficiencies of life sciences research and drug discovery.
